An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.

Keytruda (pembrolizumab) contributed almost $2.3 billion out of Merck’s total sales of $10.8 billion in the quarter, a 55% rise that was driven by use in first-line non-small cell lung cancer ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...